Marzena Chrapczyńska

Marzena Chrapczyńska

Auto-generated profile, based on publicly available information

Marzena Chrapczyńska

Maria Skłodowska-Curie Provincial Specialist Hospital in Zgierz, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
EPEmilia Przybyszewska
Emilia Przybyszewska
PPPiotr Przybyszewski
Piotr Przybyszewski
AFAgnieszka Filarecka
Agnieszka Filarecka
WWWeronika Winiarska
Weronika Winiarska
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
PPPaulina Prudzic
Paulina Prudzic
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease causing progressive joint destruction, pain, disability, and reduced quality of life. Many patients respond inadequately to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), necessitating more effective treatment strategies. Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic therapies have transformed RA management by targeting inflammatory pathways such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and Janus kinase (JAK) signaling. Methods: A narrative-systematic review of randomized clinical trials and observational studies was conducted to evaluate the efficacy and safety of biologic therapies in RA patients with inadequate response to csDMARDs. Outcomes included ACR20/50/70 response rates, Disease Activity Score in 28 joints (DAS28), remission rates, functional outcomes, and adverse events. Results: Biologic therapies significantly reduced disease activity and improved patient outcomes. TNF inhibitors combined with methotrexate achieved the most consistent efficacy, with ACR20, ACR50, and ACR70 responses reaching 78%, 57%, and 31%, respectively. Remission rates approached 40–50% in several studies. IL-6 inhibitors and JAK inhibitors provided rapid pain relief and functional improvement. Overall, remission or low disease activity was achieved in 30–60% of patients. Although biologic therapies increased the risk of adverse events, particularly infections, their safety profile remained acceptable with proper monitoring. Discussion: The findings demonstrate that biologic and targeted therapies represent a major advancement in RA treatment, particularly in patients resistant to conventional therapies. Differences in efficacy and safety profiles support individualized treatment selection, while methotrexate combination therapy may further enhance clinical response. Conclusion: Biologic therapies substantially improve disease control, physical function, and quality of life in RA patients. TNF inhibitors, IL-6 inhibitors, and JAK inhibitors remain central to modern RA management, although continued long-term safety monitoring and personalized therapeutic strategies are essential.

21 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAleksandra Siegmund
Aleksandra Siegmund
MCMarzena Chrapczyńska
Marzena Chrapczyńska
AFAgnieszka Filarecka
Agnieszka Filarecka
PPPiotr Przybyszewski
Piotr Przybyszewski
EPEmilia Przybyszewska
Emilia Przybyszewska
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
Background. Social media use among children and adolescents has expanded rapidly over the past decade, but most empirical work has examined screen time as a single construct, ignoring meaningful differences between platforms. Objective. This systematic review examined whether use of TikTok, Instagram, and YouTube is associated with distinct mental health outcomes in young people aged 6–18 years. Methods. PubMed and Google Scholar were searched between January and March 2026 in line with the PRISMA 2020 guidelines. Eligible records reported quantitative or qualitative data on at least one of the three platforms in relation to depression, anxiety, body image, self-esteem, problematic or addictive use, or general wellbeing. Methodological quality was rated with the Newcastle–Ottawa Scale for observational studies and AMSTAR-2 for evidence syntheses. Of 257 identified records, 32 met the inclusion criteria. Results. TikTok use was the most consistently linked to harm: depressive and anxiety symptoms, problematic use, and body-image disturbance, with a particularly strong contribution from algorithmic content delivery. Instagram findings centred on appearance comparison, body dissatisfaction, and self-criticism, and these effects tracked content type more closely than time on the platform. YouTube produced a more heterogeneous picture, including improvements in mental health literacy alongside concerns about uneven information quality and exposure to body-related content such as mukbang videos. Conclusion. Total time on social media is a poor proxy for risk. Platform design, content type, and algorithmic curation appear to drive distinct outcomes, and policy and clinical responses should be tailored accordingly.

17 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MCMarzena Chrapczyńska
Marzena Chrapczyńska
AFAgnieszka Filarecka
Agnieszka Filarecka
PPPiotr Przybyszewski
Piotr Przybyszewski
EPEmilia Przybyszewska
Emilia Przybyszewska
JGJulia Gatniejewska
Julia Gatniejewska
ASAleksandra Siegmund
Aleksandra Siegmund
Background: Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which antidepressants are used to modulate pathways involved in symptom generation. Evidence for their efficacy remains heterogeneous across drug classes and outcomes. Aim: To systematically evaluate the efficacy of antidepressants in the treatment of IBS across pharmacological classes and outcome domains. Methods: The methodology and reporting structure of this review were informed by the PRISMA framework. Literature searches were conducted in PubMed and Google Scholar to identify studies evaluating antidepressants in adults with irritable bowel syndrome diagnosed according to Rome criteria. Randomized controlled trials were considered the primary source of evidence and were supplemented, where relevant, by open-label, mechanistic, and exploratory studies. Eligible studies reported validated clinical outcomes, including IBS symptom severity, abdominal pain, global improvement, and health-related quality of life. Owing to differences in study design, interventions, and outcome measures, findings were synthesized qualitatively. Results: Tricyclic antidepressants (TCAs) demonstrated the most consistent signal of benefit, particularly for IBS symptom severity, global improvement, and abdominal pain. Selective serotonin reuptake inhibitors (SSRIs) showed inconsistent findings across trials, with effects varying by outcome measure and study design. Evidence for serotonin–norepinephrine reuptake inhibitors (SNRIs) was limited, often derived from add-on or open-label studies, although some randomized trials reported improvements in symptom severity and quality of life. Data for other antidepressants were restricted to a small number of RCTs with endpoint-specific effects. Variability in outcome measures, including IBS-SSS, adequate relief, and quality-of-life instruments, contributed to heterogeneity in reported treatment effects. Conclusions: Antidepressants appear to have a role in IBS management, with the most consistent evidence observed for TCAs. Findings for SSRIs are inconclusive, while evidence for SNRIs and other agents remains limited. Interpretation is constrained by variability in outcome measures and study design. Further well-designed RCTs using standardized endpoints are required to better define the role of antidepressants in IBS.

24 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
WWWeronika Winiarska
Weronika Winiarska
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
ASAleksandra Siegmund
Aleksandra Siegmund
MCMarzena Chrapczyńska
Marzena Chrapczyńska
AFAgnieszka Filarecka
Agnieszka Filarecka
MSMartyna Sienicka
Martyna Sienicka
Introduction: Hip replacement is one of the most effective treatments for advanced degenerative disease, but the optimal postoperative rehabilitation model remains a matter of debate. Objective: The aim of this study was to evaluate current rehabilitation protocols used after elective hip replacement and identify their most important and best-documented elements. Methods: A narrative literature review was conducted, encompassing 34 publications from 2015–2025, including randomized controlled trials, systematic reviews, meta-analyses, clinical guidelines, and epidemiological data. PubMed and Google Scholar databases were searched using predefined inclusion and exclusion criteria. The timing of rehabilitation initiation, type of intervention, therapy organization, and their impact on pain and functional outcomes were analyzed. Main Findings: Available evidence confirms that rehabilitation after elective hip replacement promotes improved function, independence, and pain reduction. Promising results have been reported for early mobilization, resistance exercises, functional training, and multicomponent approaches, including patient education and gait retraining. Early mobilization, often on the day of surgery, can shorten hospitalization, while training programs improve functional outcomes, as assessed by the Harris Hip Score, among other measures. However, no clear advantage of one universal rehabilitation model over others has been demonstrated. Conclusions: Rehabilitation is a key element of treatment after elective hip replacement, significantly improving function and reducing pain. Current evidence supports early, individually tailored, and comprehensive therapy, including mobilization and targeted strength training. Further high-quality methodological research aimed at standardizing treatment is necessary.

31 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AFAgnieszka Filarecka
Agnieszka Filarecka
PPPiotr Przybyszewski
Piotr Przybyszewski
EPEmilia Przybyszewska
Emilia Przybyszewska
JGJulia Gatniejewska
Julia Gatniejewska
MSMartyna Sienicka
Martyna Sienicka
MCMarzena Chrapczyńska
Marzena Chrapczyńska
Introduction: Bronchial asthma remains a significant clinical problem despite advances in pharmacological treatment. Approximately 5–10% of asthma patients suffer from a severe, uncontrolled form of the disease associated with frequent exacerbations, impaired lung function, reduced quality of life, and increased hospitalization rates. The introduction of biologic therapies targeting Th2-dependent inflammatory pathways has significantly improved treatment outcomes in this group of patients. Aim of the Study: The aim of this study was to analyze and compare the efficacy and safety of biologic therapies used in the treatment of severe asthma, with particular emphasis on tezepelumab, mepolizumab, benralizumab, and dupilumab, based on clinical trials and real-world studies. Materials and Methods: A literature review was conducted using the PubMed database. Original clinical trials, prospective studies, and real-world observational studies published between 2020 and 2026 were included in the analysis. The effects of biologic therapies on asthma exacerbation reduction, improvement in lung function, reduction in oral corticosteroid use, achievement of clinical remission, and long-term treatment safety were evaluated. Results: All analyzed biologic therapies demonstrated significant clinical efficacy in the treatment of severe asthma. Tezepelumab led to a substantial reduction in the number of exacerbations, improvement in pulmonary function parameters, and reduction in oral corticosteroid use regardless of eosinophil levels. Mepolizumab and benralizumab showed comparable efficacy, particularly in patients with eosinophilic asthma. Dupilumab demonstrated high efficacy in patients with type 2 inflammation, especially regarding improvement in lung function. Real-world studies confirmed the effectiveness and favorable safety profile of biologic therapies observed in randomized clinical trials. Conclusions: Biologic therapies constitute an effective and safe treatment option for severe asthma and significantly improve disease control and patients’ quality of life. The strongest clinical evidence concerns tezepelumab, mepolizumab, benralizumab, and dupilumab; however, treatment efficacy may depend on the disease phenotype and inflammatory biomarkers. Further studies are needed to optimize the personalization of biologic therapies and to standardize remission criteria in severe asthma.

20 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JGJulia Gatniejewska
Julia Gatniejewska
MSMartyna Sienicka
Martyna Sienicka
PPPaulina Prudzic
Paulina Prudzic
WWWeronika Winiarska
Weronika Winiarska
WBWiktoria Bełcikowska-Skowron
Wiktoria Bełcikowska-Skowron
EPEmilia Przybyszewska
Emilia Przybyszewska
Introduction: Irritable bowel syndrome is characterized by symptoms such as abdominal pain associated with defecation and changes in stool frequency and/or consistency. In recent years, the low-FODMAP diet has become one of the most commonly used dietary interventions. Aim of the study: The aim of this study was to assess the effectiveness of the low-FODMAP diet and to identify its limitations and consistency with current guidelines. Methods: A narrative review of the literature was conducted, including 31 publications from 2012–2026, such as original research articles, randomized controlled trials, systematic reviews, meta-analyses, and current clinical guidelines on the diagnosis and treatment of IBS. PubMed and Google Scholar databases were searched using predefined inclusion and exclusion criteria. Main findings: The results of the analyzed studies indicate that the low-FODMAP diet may reduce IBS symptoms such as bloating, abdominal pain, and intestinal discomfort. However, no clear superiority over other dietary strategies has been demonstrated. Clinical response varies and may depend on the patient’s gut microbiota. Data on the use of the low-FODMAP diet in the pediatric population and other special clinical groups are limited and do not allow definitive conclusions to be drawn. Conclusions: The low-FODMAP diet is an effective therapeutic option in selected patients with IBS; however, it should be implemented in stages, including elimination, reintroduction, and personalization phases. Supervision by a dietitian and individual adjustment of recommendations to the patient’s needs are recommended. Further studies are needed to assess the long-term effects of the diet and predictors of clinical response.